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Abstract
Despite the effectiveness of combination antiretroviral treatment (cART) against HIV-1, evidence indicates that residual
infection persists in different cell types. Intensification of cART does not decrease the residual viral load or immune
activation. cART restricts the synthesis of infectious virus but does not curtail HIV-1 transcription and translation from either
the integrated or unintegrated viral genomes in infected cells. All treated patients with full viral suppression actually have
low-level viremia. More than 60% of treated individuals also develop minor HIV-1 –associated neurocognitive deficits
(HAND) due to residual virus and immune activation. Thus, new therapeutic agents are needed to curtail HIV-1 transcription
and residual virus. In this study, luteolin, a dietary supplement, profoundly reduced HIV-1 infection in reporter cells and
primary lymphocytes. HIV-1inhibition by luteolin was independent of viral entry, as shown by the fact that wild-type and
VSV–pseudotyped HIV-1 infections were similarly inhibited. Luteolin was unable to inhibit viral reverse transcription.
Luteolin had antiviral activity in a latent HIV-1 reactivation model and effectively ablated both clade-B- and -C -Tat-driven
LTR transactivation in reporter assays but had no effect on Tat expression and its sub-cellular localization. We conclude that
luteolin confers anti–HIV-1 activity at the Tat functional level. Given its biosafety profile and ability to cross the blood-brain
barrier, luteolin may serve as a base flavonoid to develop potent anti–HIV-1 derivatives to complement cART.
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Introduction
HIV-1 infection of the host cells proceeds with reverse
transcription, viral DNA integration into the host genome,
transcription, translation, proteolytic processing of viral proteins
and subsequent assembly into nascent viral particles [1]. To a
large extent, the introduction of combination antiretroviral
treatment (cART) has curtailed viral replication below the
detection limit (,50 copies/mL) and significantly reduced the
devastating impact of HIV-1 [2–5]. cART works by blocking
infection of susceptible new cells, while the decay rate of plasma
virus is determined by the life span of previously infected cells [6].
However, given the presence of intact HIV-1 reservoirs, including
quiescent CD4+ T lymphocytes, bone marrow and brain [7–8], as
well as the development of viral escape mutants and drug
resistance, viral replication goes unchecked by intensive therapy
[9–14]. All treated patients with full viral suppression actually have
low-level, steady-state viremia [10,15–16].
Given the long duration of treatment, virus develops drug
resistance at multiple steps resulting in treatment failure. The
HIV-1 transactivator of transcription (Tat) protein engages
positive transcription elongation factor b (pTEFb) complex (cycT1
and CDK9), increasing RNA pol II activity and driving viral
transcriptional elongation [17–19]. Tat activity is enhanced by
host factors such as Tat-associated histone acetylases (TAH),
p300/CBP, GCN5, and P/CAF, as well as P300/CBP and GCN5
acetylate Tat at Lys 50 and 51 [20–23]. P/CAF acetylates Lys 28
on Tat and increases its ability to recruit pTEFb complex [20–22].
Thus, Tat is an important therapeutic target, having the ability to
interrupt the viral life cycle. Coincidentally, no effective HIV-1
transcriptional inhibitor is yet available to complement cART.
Thus, the alternative to keeping the virus in an under-expressed
state until the infected cells have died is to inhibit HIV-1
transcription and subsequent viral protein synthesis, which
requires new inhibitors.
Flavones, a class of flavonoids containing a characteristic 2-
phenylchromene-4-one ring structure (Fig. 1a), are found in many
herbs. They have shown therapeutic value, including antiviral
and anti-inflammatory properties [24–27]. Luteolin (2-(3,4-
Dihydroxyphenyl)- 5,7-dihydroxy-4-chromenone), myricetin,
and quercetin, which are structurally related flavones (Fig. 1a),
act as anti-oxidants and free-radical scavengers, dramatically
reducing inflammatory responses [24–25,28–32]. Their anti-
oxidant property is related to the number and position of their
hydroxyl groups [33]. Luteolin occurs in parsley, artichoke leaves,
celery, peppers, olive oil, rosemary, lemons, peppermint, sage,
and thyme; it acts as an anti-oxidant and anti-viral agent and is
now being used in clinical trials for the inhibition of neuro-
inflammation [24,29]. Luteolin also has been found to have anti-
HIV-1 activity [31,34]. Although luteolin is a promoter of
carbohydrate metabolism and an immune system modulator, it
has been shown to have potent anti-inflammatory activity by
inhibiting nuclear factor kappa B (NF-kB) in macrophages and
other immune cells [35–36].
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e27915In addition, luteolin was shown to be effective against SARS
coronavirus in a study using recombinant HIV-1 pseudotyped
with SARS CoV envelope [27]. Another study found HIV-1
protease inhibitor activity in cell-free assays, but this has not been
validated in infection studies. Moreover, the precise mechanism of
HIV-1 inhibition is unclear [34]. Flavonoids (quercetin, -myricetin
and luteolin) are structurally closely related; they are being used as
dietary supplements in the United States. They have also been
investigated for their anti-HIV-1 activity and its possible
mechanism of action. Although we found that these three
flavonoids are nontoxic and have anti-HIV-1 activity. Luteolin
was the most potent and inhibited HIV-1 infection by abrogating
Tat-mediated LTR activity.
Results and Discussion
Given the long-term persistence of intact HIV-1 reservoirs,
along with the development of viral escape mutants and drug
resistance, viral replication goes unchecked even by intensive
therapy [9–14,37]. Uninterrupted lifelong anti HIV-1 treatment
has resulted in longer survival but, with the persistence of residual
viral activity and immune activation [37], more than 60% of
cART-treated individuals develop minor cognitive disorders [38].
In addition, anti-HIV treatment leads to immune reconstitution
inflammatory syndrome (IRIS) in a substantial number of African
patients [39–40]. Above all, development of drug resistance by
HIV-1 is commonly encountered during long–term treatment.
Thus, a continuing search for new therapeutic agents to target
novel viral life cycle stages is needed.
The use of naturally occurring compounds such as a dietary
supplement having anti-HIV-1 and anti-oxidant properties
potentially provides an attractive therapy in combination with
cART. We have investigated the ability of flavonoid compounds
(Fig. 1A) to alter HIV-1 activity in screening assays using LTR-
luciferase (TZM-bl) reporter cells and primary lymphocytes as
infection models. TZM-bl cells are HeLa cells that stably express
CD4 and CXCR4 receptors. They contain an integrated copy of
the HIV-1 long terminal repeat (LTR) fused with luciferase and
beta galactosidase genes [41]. Expression of the indicator
luciferase gene is under the control of LTR via transactivator
Tat protein, which is synthesized by either the viral infection or the
plasmid expression vector. TZM-bl cells were treated for 30 min
with luteolin, quercetin, or myricetin at 5 mM and 10 mM
concentrations before HIV-1 infection. Forty-eight hours later,
the infected reporter cells were monitored for LTR activity using
luciferase reporter assay. Intriguingly, all of the flavonoid
compounds at 5 and 10 mM concentrations showed anti-HIV-1
activity, but luteolin was the most potent (Fig. 1B). HIV-1
inhibition by luteolin was specific, as vehicle control (DMSO) had
no effect on LTR activity. To rule out interference by toxicity, we
monitored cell viability after flavonoid treatments, using the
WST8 cell–viability assay [42] on TZM-bl cells. None of the
compounds showed any cellular cytotoxicity at 10 mM concentra-
tions (Fig. 1C). Although, luteolin showed slight toxicity in TZM-
Figure 1. Inhibition of HIV-1 by flavonoids. (A) Chemical structures of flavone and its derivative flavonoids. (B) HIV-1 infection in LTR-luciferase
TZM-bl reporter cells after 48 h treatment with luteolin (LN), myricetin (MN), or quercetin (QN), using DMSO as vehicle (Veh) or AZT (positive control).
Results were plotted as mean 6 SEM of duplicate readings normalized with cell control. (C) TZM-bl cell viability was assessed using WST-8 assay
(Dojindo) after treatment for 24 and 48 h with flavonoids (10 mM); in parallel, H2O2 was used as positive control. Results are shown as percent viability
relative to cell control (n=3). **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0027915.g001
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cells (Fig. 2A) and lymphocytes, to be relatively nontoxic. The
toxicity of luteolin in TZM-bl cells could result from the presence
of multiple stable constructs in these cells. Moreover, earlier
studies on several cell systems have reported that luteolin in
concentrations up to 100 mM [43] had no adverse effects. Our
data suggest that the flavonoids actively inhibited HIV-1 activity,
possibly through malfunctioning of Tat activity. This could be due
to blockage at any step in the viral life cycle.
Infurtherstudies,weexaminedthe anti-HIV-1activityofluteolin
in greater detail. We tested different concentrations of luteolin (0–
40 mM) on cell viability in different cell models to find a workable
nontoxic concentration. Luteolin in concentrations between 5 and
10 mM, the upper limit for therapeutic agents used in screening
assays, had significant antiviral activity. Thus, we used luteolin at 5
and 10 mM for all experiments(Fig. 2).We confirmed theanti-HIV-
1 activity of luteolin in infection assays in lymphocytic cells and
primary human lymphocytes using either wild-type (NLENG1) or
VSV-pseudotyped HIV-1. In infection studies, we used HIV-1
NLENG1 containing GFP gene cloned between the envelope and
nef region [44,45]. Thus, we could monitor productive viral gene
expression not only by GFP expression, using fluorescence
microscopy, but by HIV-1 p24 capsid protein in the supernatants,
which was detected by ELISA [42,44].
Figure 2. Luteolin inhibited HIV-1 infection in Jurkat cells. A. Viability of TZM-bl, Hela, and Jurkat cells after treatment with different
concentrations of luteolin (0–40 mM) for 24–48 h as determined by WST8 -assay (n=3). B–D. Jurkat cells were pretreated for 30 min with 5 mMo r
10 mM luteolin (LN5 and LN10, respectively), vehicle (DMSO), or AZT (positive control) followed by HIV-1 infection for 2 h at 37uC. HIV-1 infection was
monitored by (C) GFP expression or (D) virus release in supernatants as determined by p24 ELISA on the 5
th day post-infection. GFP quantification
was done by counting 10 random low-power fields and plotted as mean 6 SEM (n=2).
doi:10.1371/journal.pone.0027915.g002
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30 min followed by HIV-1 infection, as reported earlier [42]. After
infection, luteolin treatments were maintained for 3–5 days, the
duration of the experiment. Luteolin treatment markedly reduced
the HIV-1 infection in Jurkat cells (Fig. 2B–D) in a dose-dependent
manner as shown by reductions in both the number of GFP-
positive cells and viral p24 release in the supernatants on the fifth
day after infection. To confirm these above findings and also rule
out the cell–specific inhibition of HIV-1, we infected TZM-bl cells
and obtained similar suppression of viral infection (Fig. 3A–D).
Although treatment with luteolin prior to HIV-1 infection had no
additional advantage on virus replication as compared with
overnight treatment after HIV-1 infection (Fig. 3C, D). Instead
better HIV-1 inhibition was seen with the latter, indicating that
luteolin may affect the later stages of the HIV-1 life cycle rather
than restricting the virus at the receptor, reverse transcription or
viral DNA integration steps.
To test this possibility, we did infection studies on primary
human lymphocytes using wild type virus and additionally VSV-
NLENG1 (HIV-1) was used to facilitate rapid and homogeneous
receptor-independent viral infection. Before these studies, we
confirmed that luteolin was non-toxic to primary cells (Fig. 4A).
We treated wild-type and VSV-HIV-1 infected lymphocytes with
5 and 10 mM of luteolin until follow-up and monitored for viral
infection by GFP expression and the release of p24 in culture
supernatants (Fig. 4B–D). Luteolin treatment alleviated HIV-1
infection (wild–type or VSV-HIV) as shown by a reduction in GFP
expression (Fig. 4B) and p24 levels in the supernatants following
virus release at 2, 4, and 6 days after infection (Fig. 4C, D). In
parallel, 5, 6- dichloro- 1-b -D-ribofuranosyl-1H-benzimidazole
(DRB), a transcriptional inhibitor (RNA pol II inhibitor) was used
as a positive control, while vehicle (DMSO) was used as a solvent
control. DRB suppresses HIV-1 transcription by inhibiting RNA
polymerase activity [46–47]. Interestingly, luteolin treatment of
HIV-1 infected lymphocytes also showed inhibition in cell
aggregation/syncytia similar to that produced by DRB and cell
control (Fig. 4B), suggesting that viral envelope (gp120) protein
expression on cell surfaces is impaired. Viral gp120 expression on
infected cells is required for syncytia formation or aggregation of
cells. In addition, luteolin did not affect the proliferation of
lymphocytes during viral inhibition studies.
Our results thus far indicated that the mechanism of luteolin-
mediated HIV-1 suppression is independent of viral entry
receptors. To corroborate the effect of luteolin on wild–type virus,
TZM-bl reporter cells were pretreated with luteolin or DMSO for
30 min, then infected with HIV-1 (p24=250 ng/ml). We assessed
the effect of luteolin on virus entry after 6 h of infection by the
accumulation of intracellular viral capsid (p24), which was
quantified by ELISA in HIV-1 —infected cell lysates. As a
positive control for entry inhibition, we pretreated TZM-bl cells
with a CXCR4 blocker, AMD 3100, before infecting them with
HIV-1. Luteolin (5–10 mM) pretreatment did not have a
significant effect on wild–type HIV-1 entry as compared to that
in untreated infected cultures (Fig. 5A). To rule out the possibility
of contamination from cell-membrane-bound virus particles in the
cell lysates, we tested p24 levels in HIV-1-infected cell superna-
tants (HIV-sup) at 6 h after infection and found barely detectable
levels (Fig. 5A).
The preceding results showed that luteolin inhibited HIV-1
infection independent of viral entry. We then investigated whether
luteolin had any effect on viral reverse transcription. After
infecting TZM-bl cells with HIV-1 for 2 h and treating them
with luteolin, we monitored the levels of reverse-transcribed
intracellular HIV-1 DNA at 6 h after infection, using real-time
PCR [48]. In this situation, unlike that when we used AZT, a
reverse transcriptase inhibitor (positive control), treating HIV-1
infected TZM-bl cells with luteolin did not significantly alter the
amount of reverse transcribed HIV-1 DNA (Fig. 5B). This
suggested that luteolin was unable to annihilate viral reverse
transcription.
We then investigated the effect of luteolin on viral integration,
first testing viral integration kinetics in VSV-pseudotyped HIV-1-
infected Jurkat cells from 0 to 24 h using semiquantitative Alu-
integration PCR, with GAPDH as an internal control [44]. The
minimum PCR amplification cycles were optimized to obtain the
amplification product in linear log phase. Densitometric analysis of
amplified PCR products showed that viral integration was rapid in
Jurkat cells, starting within just 4 h after infection (Fig. 5C). This is
consistent with earlier findings on VSV-HIV-1 [49]. However, our
results suggest that the peak integration levels are reached by 8–
10 h after infection, slightly longer than in an earlier study [49].
These differences could be due to use of different HIV-1 strain in
the above study.
To test the effect of luteolin on viral integration, we infected
Jurkat cells with VSV-pseudotyped HIV-1, then treated the cells
with either luteolin or vehicle at times ranging from 4 to 12 h.
After 24 h, viral infection was monitored by GFP expression and
viral integration, using Alu-LTR PCR as described (Fig. 5D, E). In
parallel, we used integrase-defective mutant HIV-1 (D64A) as a
control [50,51]. As compared to vehicle controls, luteolin-
mediated suppression of HIV-1 expression was evident irrespective
of the time after infection when treatment was initiated (4–12 h)
(Fig. 5D). The weak suppression in integration signal as compared
to that in untreated infected cells (Fig. 5E) was in contrast to a
previous report showing exclusive effect on viral integration [31].
Figure 3. Luteolin inhibited HIV-1 infection in TZM-bl reporter
cells. TZM-bl cells were pretreated for 30 min with 0, 5, and 10 mM
luteolin, then infected with HIV-1 for 2 h at 37uC. HIV infection was
monitored by (A) GFP expression or (B) virus released in supernatants
as determined by p24 ELISA on 3
rd day post- infection (n=3). C, D.
TZM-bl cells were pre- or post-treated with luteolin (10 mM) followed by
HIV-1 infection. (C) At 72 h post-infection, HIV-1 infection was
monitored by GFP expression. (D) Culture supernatants were analyzed
for the virus p24 antigen by ELISA. (n=2).
doi:10.1371/journal.pone.0027915.g003
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with luteolin at 12 h post-infection suggests that luteolin has an
inhibitory effect on the HIV-1 life cycle mainly if not exclusively at
the postintegration stage.
Given that integration was already complete within 8–10 h
post-infection (Fig. 5C), we further explored the effect of luteolin
on post-integration steps of the HIV-1 life cycle. To investigate
HIV-1 replication independent of viral DNA integration, we
transfected TZM-bl cells with HIV-1 DNA expression vector.
After treating the cells with luteolin or vehicle control (DMSO),
we monitored viral gene expression using the LTR-luciferase
assay. In this system, Tat expression from HIV-1 DNA drives
LTR-luciferase expression, which was quantified luminometri-
cally. Luteolin treatment markedly inhibited HIV-1 gene
expression (or at least Tat expression) as compared to that in
control TZM-bl reporter cells (Fig. 6A). Given that HIV-1
plasmid DNA expression vector replicates independently of viral
DNA integration, it is evident that luteolin inhibited either Tat
expression or Tat function at the LTR level, but not HIV-1 DNA
integration.
To validate the HIV-1 plasmid DNA expression results, we did
infection studies in which VSV-pseudotyped HIV-1 wild-type
viruses or envelope-deficient HIV-1 viruses were used on TZM-bl
reporter cells. As compared to controls, luteolin-treated VSV-
HIV-1-infected reporter cells profoundly suppressed the Tat-
regulated luciferase signal similar to that in HIV-1 plasmid DNA
transfection (Fig. 6A), suggesting aborted viral replication. DMSO
controls also showed some suppression in luciferase signal in both
HIV-1 DNA transfected and VSV-virus infected TZM-bl cells.
One possibility is that DMSO affects luciferase expression either at
the mRNA level or via CMV promoter. However, we confirmed
our HIV-1 inhibition results on Magi cells (CD4/CCR5+ve HeLa
cells) using GFP and viral p24 as markers. We transfected these
cells with recombinant HIV-1 plasmid DNA vector expressing
GFP (NLENG1), then treated them with luteolin for 12–24 h. At
48 h after transfection, we monitored GFP expression and viral
p24 antigen in the supernatants, finding that luteolin treatment
suppressed both (Fig. 6B, C), which suggested inhibition at the
post-HIV-1 DNA integration step. We are convinced that small
inhibition in DMSO-treated VSV-HIV-1 infected cultures or
Figure 4. Luteolin inhibited HIV-1 infection in primary human lymphocytes. (A) Viability of primary human lymphocytes after treatment
with different concentrations of luteolin (0–40 mM) for 24–48 h as determined by MTT assay (n=2). (B–D) Luteolin inhibited HIV-1 infection in
primary lymphocytes. Primary human lymphocytes were cultured in 12–well culture plates for 6 days in PHA (1%) and IL-2 (10 ng/ml), treated either
with luteolin (10 mM) or vehicle, then infected with VSV-HIV-1 or wild–type HIV-1. Viral infection was monitored 2, 4, and 6 days post infection. In
parallel, DRB (10 mM) was used as a positive control and DMSO as a vehicle control. (B) The reduction in syncytia formation is evident (white arrows)
in luteolin and DRB-treated cells. (C, D), p24 levels in supernatants were monitored by ELISA at (C) 2 days after VSV-HIV infection. (** p,0.01). (D)4
and 6 days after wild–type HIV-1 infection of lymphocytes (*** p,0.001).
doi:10.1371/journal.pone.0027915.g004
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effect on viral (VSV) endocytosis. However, we do not underes-
timate the true effect of luteolin, which was corroborated by
inhibition of wild-type infection, HIV-1 DNA-mediated LTR
transactivation, and post-integration viral state without any
inhibitory effect of DMSO. Antiviral activity of luteolin is clearly
shown in wild–type HIV-1 infection studies wherein DMSO did
not confer any antiviral activity. These results ruled out any
additive effect of DMSO with luteolin on HIV inhibition.
Thus far, luteolin-mediated suppression of the LTR-luciferase
activity has been demonstrated after HIV-1 plasmid DNA
transfection or HIV-1 infection, suggesting that luteolin may
confer anti-viral activity at the functional level of Tat-LTR
function, Tat expression and its sub-cellular localization or
downstream viral protease. To further examine luteolin-mediated
inhibition of HIV-1 at post–DNA integration stages, we did
experiments on latently HIV-1 infected THP89 cells, in which the
HIV-1 genome contains the GFP gene. THP89 cells contain HIV-
1 provirus in a latent state without any viral gene expression
including GFP [44]. On induction by TNF-a (NF-kB activation)
or Trichostatin A (histone deacetylase inhibitor), however, viral
reactivation is initiated; cells start expressing GFP and release the
virus extracellularly [32,45,48]. After THP89 cells had been
pretreated with luteolin or DMSO for 18 h, viral reactivation was
initiated using TNF-a (10 ng/ml). TNF-a- reactivated latent HIV-
1 infection was attenuated by treatment with luteolin (10 mM),
demonstrating reduction in GFP expression and released virus
(p24) in 24, 48, and 72–h induction periods (Fig. 7A–B). This
Figure 5. Luteolin inhibited HIV-1 independently of viral entry and reverse transcription steps. A. Effect of luteolin on viral entry. TZM-bl
cells (6610
5) in six well tissue culture plates were pretreated with luteolin (5 and 10 mM) or vehicle for 1 h, then infected with HIV-1 infection
(p24=250 ng/ml) for 2 h at 37uC. After infection, cells were briefly treated with 0.2% trypsin-EDTA and washed extensively to remove cell-membrane-
bound virus particles. Six h post-infection, cells were trypsinized and lysed. p24 levels were estimated in cell lysates after normalization of protein
concentrations (BCA method) and in HIV-1 infected culture supernatant (HIV-sup). The results are presented as the amount of p24 present per mg of
proteins in cell lysates. B. TZM-bl cells (6610
5) in six–well tissue culture plates were pretreated with luteolin (10 mM) or DMSO for 30 min, then
infected with HIV-1 NLENG1 (p24, 250 ng/ml) for 2 h. At 6 h after infection, cells were treated briefly with 0.2% trypsin and washed. Genomic DNA
was harvested from HIV-infected cells. 200 ng of total DNA was used as a template for quantification of viral DNA by real-time PCR using Tat primers
and normalized to GAPDH signals. In parallel, 500 ng HIV-1 proviral DNA (pHIV) was transfected as a positive control. C. Jurkat cells (7610
5) in six–well
culture plates were infected with VSV-HIV-1 (p24=250 ng/ml) for 2 h at 37uC, washed twice, and followed up for 24 h. Cells were harvested from 0 to
24 h after infection and viral integration was monitored by Alu-LTR-PCR. D–E. Jurkat cells were infected with VSV-HIV-1 and treated with luteolin
(10 mM) or DMSO at 4, 8, and 12 h after infection. The levels of viral infection were monitored by the amount of GFP expression in luteolin- and
vehicle-treated HIV-1 infected cells (D). Viral integration was analyzed 24 h post-infection by Alu-LTR PCR (E). VSV-HIV-1 was used as positive control;
HIV-1 NL4-3 mutant (D64A) defective in viral DNA integration function (DINT HIV) was used as negative control (n=4).
doi:10.1371/journal.pone.0027915.g005
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stages; that is viral transcription or translation or Tat functional
activity. When Tat functional activity is impaired in a TNF-a —
reactivated latent HIV-1 model, GFP expression, including viral
proteins that are dependent on Tat function, will eventually be
impaired, so that p24 activity is reduced in infected culture
supernatants.
Taken together, our multiple lines of evidences indicated that
luteolin confers its anti-HIV-1 activity by inhibiting HIV-1
transcription, translation, or post–translational processing (prote-
ase). However, given our finding that GFP expression was reduced
in both TNF-a reactivated latent HIV-1 infection and acute viral
infection; the data point toward transcriptional inhibition or
translation (Figs. 2, 3, 4, 5, 6, and 7), which was not expected from
crippled viral protease. GFP is cloned between env and nef genes
[44–45] and its expression is independent of viral protease activity,
but dependent on Tat for transcription. To validate the infection
data, we examined Tat function, using only Tat expression vectors
to rule out other viral proteins. To mimic HIV-1 expressed Tat,
we packaged lentiviral-vector- expressing Tat protein pseudotyped
with VSV envelope (VSV-Tat). We used VSV-Tat viral particles
for transduction of SVGA-LTR-GFP reporter cells expressing
EGFP under the control of HIV-1 LTR [52–53]. In parallel,
VSV-pseudotyped HIV-1 was used as a positive control. Luteolin
treatment following transduction with VSV-Tat virus particles led
to suppression of LTR-mediated GFP expression (Fig. 7C),
suggesting compromise in Tat function at either the protein
expression level or the LTR-transactivation level. We corroborat-
ed these results using TZM-bl reporter cells. Transfection of
pcDNA-Tat expression vector wherein Tat is under the control of
CMV promoter, followed by treatment with different concentra-
tions of luteolin (0–10 mM), resulted in dose-dependent suppres-
sion of LTR-luciferase expression, which did not occur in vehicle-
treated or untreated cultures (Fig. 8A).
We further investigated whether luteolin affects Tat expression
levels by transfecting TZM-bl cells with Tat expression vector
(pcDNA-Tat), and treating them with either luteolin or vehicle.
Luteolin treatment had no affect on Tat protein levels as analyzed
by Western blotting (Fig. 8B), indicating that LTR transactivation
(Fig. 8A, C) is restricted at the Tat functional level. In parallel, we
co-transfected Tat siRNA with Tat expression vector (pcDNA-
Tat) as a positive control, observing suppression in Tat expression,
but not in vehicle controls (Fig. 8B).
The variation in transcriptional activity of HIV-1 Tat protein
among HIV-1 subtypes has been predominately attributed to
sequence variability in its N-terminal activation domain (1–48
amino acids), especially the cysteine–rich region, which binds Zn
2+
cation and engages cyclin T1 [54]. Tat from HIV-1 subtype-C and
E (prevalent in Asia and Africa) is reported to exhibit higher
transactivation and TAR RNA binding capacity than does HIV-1
subtype-B (prevalent in North America and Europe) [54–56].
Hence, we investigated whether luteolin-mediated suppression of
Tat-mediated LTR-transactivation can be extended to different
HIV-1 subtypes. On transfection of clade-B and C Tat expression
vectors (pcDNA-Tat vectors) abundant expression of Tat proteins
was found in TZM-bl cells (Fig. 8C, inset), with levels of LTR-
transactivation similar to those in compared to controls observed
in Western blots (Fig. 8C). In further experiments, luteolin
treatment profoundly inhibited LTR-mediated luciferase expres-
sion in both clade-B and -C Tat transfected cells (Fig. 8C). In
parallel, transcriptionally inactive Tat-47 mutant (D48–56) deleted
in nuclear localization signal was used as negative control,
demonstrating only basal luciferase activity in both Tat-47- and
empty vector (pcDNA)- transfected TZM-bl cells.
Given that Tat is a bona fide nuclear/nucleolar protein [52,57–
59], we investigated whether luteolin affects sub-localization and
thus cripples HIV-1 LTR-activity. We transfected HeLa cells
using Tat-HA vector and 6 h after transfection, then treated them
with luteolin or DMSO or left them untreated. At 24 h after
transfection, cells were immunostained for Tat, nucleophosmin
(nucleolar protein), and nuclei, then examined for Tat localization.
Tat sub-cellular (nuclear/nucleolar) localization was unaffected by
luteolin, as in DMSO- or mock- treated cells (Fig. 8D). This
indicates that viral transactivator protein function is impaired at
the LTR-functional level, including either Tat binding to TAR
RNA or cyclin T1/CDK9 or inhibition of critical factors,
including NF-kB, that are involved in HIV transcription (Fig. 9).
These observations confirm that luteolin confers its anti-HIV-1
activity at the Tat-LTR transactivation level (transcription step)
after the viral integration step. However, further investigations of
the action of luteolin are needed to decipher the detailed
mechanism of Tat-mediated LTR inhibition. Currently, we are
investigating the interactions of Tat with HIV-1 LTR and host
transcription factors, as well as post–translational modification on
Tat in the presence of luteolin. Several compounds, such as
Quinolines, as well as stilbene- and purine-derivatives have been
Figure 6. Luteolin inhibited HIV-1 gene expression indepen-
dently of viral DNA integration. A. TZM-bl reporter cells in 12 well
culture plates were transfected with HIV-1 plasmid DNA vector
expressing GFP, then treated with luteolin (10 mM) or DMSO (Veh). In
parallel, TZM-bl cells were infected with VSV-HIV NLENG1 or NLR
+E
2 for
2 h, then treated with luteolin (10 mM) or DMSO for the duration of
follow up. At 48 h post-transfection or infection, cells were lysed and
assayed for luciferase activity (n=2). B–C. Two hours after Magi cells
were transfected with pHIV NLENG1 (150 ng), luteolin (10 mM) was
added to them. After 6 h, transfection medium was replaced with fresh
medium containing luteolin for 12 or 24 h. At 48 h post-transfection,
cells were monitored for GFP expression. Representative pictures are
shown (B). Cell supernatants were collected to measure p24 levels (Cs)
(n=2). *** p,0.001, ### p,0.005.
doi:10.1371/journal.pone.0027915.g006
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tions [60–64]. Other compounds, such as flavipiridol, rescovtine,
and 9-amino acridine, targeted CDK9, a component of pTEFb
complex [65–67]. Recently, a coumarin derivative has been shown
to potently inhibit HIV Tat function in nano–molar concentra-
tions by repressing p300 and PI3K/AKT [68]. This supports the
Figure 7. Luteolin inhibited reactivation of latent HIV-1 infection. (A, B) One million latently HIV-infected THP89 cells seeded per well in 12
well culture plates were pretreated overnight with luteolin (5 or 10 mM) or DMSO, then stimulated with TNF-a (10 ng/ml) and monitored by (A) GFP
expression and (B) virus production by p24 ELISA. Similarly, 10 mM luteolin treatments were given from 12 h to 72 h post -TNF-a stimulation. Virus
production was monitored by p24 ELISA. DRB (10 mM) was used in parallel as a positive control (n=3). (C) Luteolin inhibited transactivation of
integrated HIV- LTR. SVGA-LTR-GFP reporter cells were transduced with VSV-Tat viral particles for 2 h, then treated with 10 mM luteolin or vehicle and,
after 24 h, monitored for GFP expression.
doi:10.1371/journal.pone.0027915.g007
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derivatives to inhibit HIV in nano–molar concentrations.
Therefore, several other active derivatives of luteolin shown to
have more potent antioxidant and anti-inflammatory properties
need to be investigated for anti-HIV-1 activity. Intriguingly,
quercetin, a luteolin analogue, has been shown to repress
proinflammatory miRNA-155 in macrophages in –vivo [43], it
would be interesting to determine whether luteolin has the same
effect. One caveat is that luteolin may complement combination
anti-HIV therapy by preventing synthesis of viral proteins
available for protease steps. This would enhance the potency of
protease inhibitors, eventually leading to reduced virus assembly
and release.
In conclusion, our results on reporter cells and primary
lymphocytes indicate that luteolin cripples HIV-1 Tat function
and may be the critical component in anti-retroviral combination
therapy for HIV-1 infection. In addition, luteolin crosses the
blood-brain barrier and has been shown to confer neuroprotective
effects via inhibition of neuroinflammation [28,69–71]. However,
the concentrations of luteolin that we found to be inhibitory in our
study are in the upper therapeutic ranges. Further investigation is
needed to determine whether these concentrations are achieved in
vivo. Further investigations in–vivo and significance of luteolin
with anti-HIV drugs whether it can act in synergism with lower
concentrations, are the future goals. However, we have laid the
foundation for development of luteolin derivatives that, in
nanomolar ranges, may which could inhibit HIV-1. Currently,
we are investigating the ability of 500 flavonoid derivatives to
inhibit HIV in nano molar ranges.
Materials and Methods
Primary cells, cell lines, and reagents
Human peripheral blood mononuclear cells (PBMCs) were
separated from whole blood (New York blood bank) using
Histopaque (Sigma, St., MO), washed three times with phos-
Figure 8. Luteolin inhibited clade B and –C Tat–mediated LTR transactivation in TZM-bl reporter cells. (A) TZM-bl reporter cells were
transfected with Tat expression vector (pcDNA-Tat) and treated after 4 h with different concentrations of either luteolin (0–10 mM) or vehicle and
monitored for luciferase activity. (B) TZM-bl cells were transfected with pIRES2-EGFP-Tat-HA (400 ng) and, 24 h later, treated with 0-, 5- and 10- mM
luteolin. A Tat-specific siRNA cocktail of 3 siRNAs (300 nM) was co-transfected with Tat expression vector as a positive control. 48 h post-transfection,
cells were harvested for Western blot using anti-HA and anti-b actin antibody. (C) TZM-bl cells transfected with HIV-1 subtype-B or -C Tat expression
vectors (pcDNA-Tat) were treated with luteolin (10 mM) at 4 h after transfection. In parallel, mutant Tat-47 (D 47–56 aa) was used as a negative
control. LTR luciferase activity was assessed at 48 h after transfection. Protein levels expressed from Tat expression vectors were monitored by
Western blot with anti-HA and anti-b-actin antibody. *** p,0.001. (D) Effect of luteolin treatment on subcellular localization of Tat protein in HeLa
cells. Immunostaining showing subcellular localization of Tat protein in HeLa cells after treatment with luteolin (10 mM), DMSO as a vehicle control
(DMSO), or untreated (-). IgG was used as isotype antibody control (Isotype). Cells were immunostained for Tat (red), B23/nucleophosmin (green), and
nuclei (blue), images were captured at 206with a Nikon fluorescent microscope.
doi:10.1371/journal.pone.0027915.g008
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RPMI as previously described [42]. TZM-bl (CD4/CXCR4/
CCR5+ve HeLa cells) and Jurkat cells were obtained through
AIDS Reagent and Reference Program, NIH. TZM-bl, SVGA-
LTR-GFP cells [52] were grown in DMEM while Jurkat cells were
grown in RPMI with 2 mM L-glutamine and RPMI (Gibco-BRL),
each supplemented with 10% FBS, 1% penicillin, streptomycin,
and amphotericin B (GibcoBRL). We obtained all chemical
reagents from Sigma (St. Louis, MO). Stocks for luteolin,
quercetin, and myricetin were prepared in dimethyl sulphoxide
(DMSO). All flavonoids used in the study were of more than 98%
purity. Rabbit polyclonal anti-HA antibodies were purchased from
Santa Cruz Biotechnology, mouse anti-B23 (nucleophosmin)
antibody from Abcam, Alexa 568 conjugated goat anti-rabbit
IgG, and Alexa 488 conjugated goat anti-mouse IgG from
Invitrogen. We purchased mouse monoclonal anti b-actin
antibody from Sigma.
Viral constructs and plasmids
We obtained HIV-1 NL 4-3.HSA.R
+E
2 [72], subtype C Tat
[73], and VSV-G expression plasmids [74] through the National
Institutes of Health (NIH) AIDS Reagent and Reference Program.
The use of HIV-1 NLENG1 has been described [44], as the use of
NL4-3 integrase mutant (D64A) [50]. Full-length subtype B Tat
(101 amino acids) was subcloned from pcDNA-Tat [53] into HIV-
1 derived lentiviral vector pLVX (Clontech) under CMV
promoter and packaged with a VSV envelope as described earlier
[48]. HA tag was inserted at the C-terminus of full-length subtype
B and subtype C Tat, along with EcoRI and XhoI restriction sites
by PCR amplification. Amplicon was cloned into pcDNA3.0
vector. Similarly, subtype B Tat with HA tag was subcloned into
bicistronic pIRES2-EGFP vector (Clontech). Functionally inactive
subtype B mutant was created by deletion of nuclear localization
signal (amino acids 47–56) and was cloned with HA tag in
pcDNA3.0 vector at EcoRI and XhoI sites. The inserts were
confirmed by double–strand DNA sequencing. The HIV-1 long
terminal repeat (LTR)-driven GFP construct was created by
replacing CMV promoter in the pEGFP-N1 vector (Clontech)
with LTR promoter at SalI and SmaI, then stably transfected into
SVGA cells [53].
Virus packaging, pseudotyping, and HIV-1 infection assay
HIV-1 full length DNAs or lentiviral vector pLVX expressing
Tat were packaged in 293T cells as described previously [42].
Briefly, we transfected 17 mg of HIV or lentiviral expression vector
DNA per 100 mm culture dish (BD Falcon) using Lipofectamine
2000 (Invitrogen). Similarly, we pseudotyped HIV-1 NLENG1 or
HIV-1 pNL4-3.HSA.R
+.E
2 proviral DNA (17 mg) with VSV-G
envelope using a 4.0 mg VSV-G construct. To pseudotype
lentiviral vector, cells were transfected with 10.0 mg pLVX-Tat
or pLVX with 3.0 mg pCMV-Tat, 8.0 mg pGag-Pol, 4.0 mg
pCMV-Rev, 2.5 mg pVpr, and 4.0 mg pVSV-G using Lipofecta-
mine 2000 [42]. The supernatants containing viral particles were
harvested 72 h after transfection and centrifuged at 300 g for
10 min to remove cellular debris. Further, viral stocks were treated
with 5 IU/ml of RNase-free DNase for 15 min at room
temperature and membrane–filtered. Stocks were filtered and
stored as 1.0 ml aliquots at 280uC. Viral titers were determined
by p24 ELISA (Zeptometrix, Buffalo, NY) or by transducing
SVGA-LTR-GFP reporter cells.
HIV-1 infection in either TZM-bl or Jurkat cells was done in
12-well tissue culture plates (Falcon) with HIV-1 NLENG1
(250 ng/ml p24 antigen) for 2 h at 37uC. After infection, cells
were washed twice with optiMEM and replaced with complete
medium containing 10% FBS. On the next day, medium was
replaced once to remove input-adsorbed virus particles released
during the 24-h period. We collected supernatants on the third
and fifth days after infection. p24 antigen was monitored in HIV-1
infected culture supernatants by quantitative ELISA (Zeptome-
trix). GFP expression was monitored and the images captured by a
digital camera in a fluorescent microscope (Nikon). Primary
human lymphocytes were cultured from PBMCs and stimulated
with 1% PHA and IL-2 (10 ng/ml) [42], then infected with wild–
type HIV (NLENY1) or VSV-HIV-1 for 2 h at 37uC, then
washed. Productive virus infection was monitored at 2, 4, and 6
days after infection by p24 ELISA.
Western blotting and immunofluorescence
TZM-bl cells were transfected with pIRES2-EGFP-Tat-HA
and, on the next day, treated them with luteolin or DMSO. Cells
were harvested 48 h after transfection and lysed in RIPA buffer
(Sigma) containing a protease inhibitor cocktail (Pierce); 30 mgo f
total protein from each sample was then analyzed on 12% SDS-
PAGE. Protein bands were transferred to polyvinylidene difluoride
(PVDF) membranes (BioRad) [48]. We blocked the membranes
with blocking buffer (5% nonfat dry milk, 0.1% Tween 20 in PBS)
for 1 h at room temperature. Overnight, the membranes were
probed at 4uC with rabbit polyclonal antibody against HA peptide
(1:1000, Santa Cruz Biotechnology) and, as an internal control,
mouse monoclonal antibody against beta actin (1:3000 dilution,
Sigma). After three washes with 0.1% Tween 20 in PBS, the
membranes were incubated with anti-rabbit IgG secondary
antibody conjugated to horseradish peroxidase (1:3,000, BioRad)
in blocking buffer for 1 h at room temperature. We washed the
membranes three times with 0.1% Tween 20 in PBS and
developed them using a chemiluminescence detection kit ECL
(GE Healthcare). Tat levels were quantified by densitometric
analysis using Image J software (NIH). Normalization of samples
was done at two levels using equal protein concentrations for
loading followed by actin levels.
Figure 9. Proposed schematic representation of anti-HIV
activity of luteolin. After HIV-1 DNA integration into host genome,
viral genes are expressed under the control of the HIV-1 long terminal
repeat (LTR) as a promoter with the help of viral regulatory protein Tat,
which binds with TAR RNA element in the 59 end of LTR. Luteolin may
abrogate Tat-mediated LTR transactivation activity by interfering with
pTEF-b binding with LTR or abolish Tat binding; it also may prevent NF-
kB activation or inhibition of host factors involved in transcription or
inhibition of viral mRNA translation.
doi:10.1371/journal.pone.0027915.g009
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[44]. HeLa cells seeded in slide flaskets (Nunc, Denmark) were
transfected with 500 ng of pcDNA-Tat-HA expression vector
using Lipofectamine 2000. At 24 h after transfection, cells were
fixed with 2% paraformaldehyde for 15 min at 25uC. The cells
were washed twice with PBS and permeabilized by Triton X-100
(0.2%; v/v) in PBS for 11 min. Slides were overlaid with primary
antibodies against HA (rabbit) and B23/nucleophosmin (mono-
clonal) as a nuclear maker, and each antibody diluted to 1:300.
Slides were kept overnight at 4uC. In parallel, IgG1 antibody was
used as an isotype antibody control. The slides were washed three
times with PBS and overlaid with alexa-568 conjugated goat-anti-
rabbit (1:500) and alexa-488 conjugated goat-anti-mouse (1:500),
then incubated at 25uC for 35 min. After two washings, nuclei
were stained using Hoechst (1 mg/ml) for 5 min. Slides were
mounted in fluoromount (Sigma), an aqueous gel mounting
medium. Slides were examined with Nikon E600 fluorescence
microscope and images acquired at 206magnification.
HIV-LTR reporter assay
We infected TZM-bl cells with HIV-1 (p24=250 ng/ml) or
transfected them with Tat expression vector using Lipofectamine
2000 (Invitrogen) [53] either in 96-well or 12-well plates, then
treated the cells with luteolin or vehicle control. The DNA
concentrations in transfection were normalized using empty
control vector (pcDNA). At 48 h after treatment, we lysed cells
using reporter lysis buffer (Promega), then put them through one
freezing-thawing cycle. 30 ml of cell lysates was used to monitor
luciferase activity in a 100-ml reaction using ready-glow firefly
luciferase substrate (Promega). We quantified the luminescence in
optilux black plates (Falcon) using a multi-mode microplate reader
(BioTek instruments), then calculated the percent of LTR
luciferase activity as relative luciferase units normalized to cell
control.
Real-time PCR and Alu-HIV-1 integration PCR
To detect viral DNA synthesis after reverse transcription in
HIV-1 infection studies, we did real-time PCR as described earlier
[48]. Briefly, we harvested DNA from the infected cells using
DNAzol (Invitrogen) [48]. The cells were removed by trypsiniza-
tion and washed twice with PBS, after which we added 1.0 ml
DNAzol to cell pellets. DNA was precipitated by adding 500 ml
ethanol, removed by spooling with a pipette tip, and washed once
with 70% ethanol. DNA was dissolved in 8 mM NaOH (pH 8.0)
and spectrophotometrically quantified. The amount of viral DNA
in the samples was quantified by real-time PCR [75] using Tat
gene-specific primers. The following primer sets were used:
Tat forward: 59-GAAGCATCCAGGAAGTCAGCC-39
Tat reverse: 59-ACAAACTTGGCAATGAAAGCAACAC-39
GAPDH forward: 59-CATCAGCAATGCCTCCTGCACC-39
GAPDH reverse: 59-GTGCTCAGTGTAGCCCAGGATG-39.
Briefly, 200 ng of genomic DNA was used in 30-ml PCR
reaction mix in triplicate with 10 pmol of each primer and 26sybr
green (SA Biosciences). The cycle program for amplification was
95uC/3 min followed by 45 cycles of 95uC/20 sec, 60uC/20 sec
and 72uC/20 sec. The reactions were run on a CFX96 real-time
PCR system (Bio-RAD). Data were collected and analyzed using
Bio-RAD CFX Manager Software v 1.1. Ct values were calculated
for each gene and normalized relative to GAPDH expression.
Results were presented as mean 6 SEM of two separate
experiments. Fold expression from untreated controls was
calculated by the 2
2DDCt method [75].
To examine HIV-1 DNA integration, semiquantitative nested
Alu-HIV-1 integration PCR was done as described previously
[44,76], but with slight modifications. The following primers were
used for the first round of amplification:
INT-1: 59- TGCTGGGATTACAGG GCGTGAG-39
INT-2: 59-TAGACCAGATC- TGAGCCTGGGA-39.
The primers for second round were;
INT-N1: 59-GGCTAACTAGGGAAC-CCACTG-39
INT-N9, 59-CTGCTAGAGATTTTCCACACTGAC-39.
We used 200 ng of genomic DNA as a template for
amplification with the first set of Alu-HIV-1 PCR primers in a
50-ml PCR mix. Amplification cycles were 96uC/3 min followed
by 16 cycles of 96uC/45 sec, 60uC/15 sec, and 72uC/50 sec. In
the nested step, 1.0 ml of the first PCR product was used as a
template in a 50-ml reaction volume in duplicate and was amplified
for 25 cycles using a similar PCR protocol as noted earlier. For all
sample sets, GAPDH was amplified as an internal control from
200 ng genomic DNA as a template using the cycle program as
96uC/3 min followed by 25 cycles of denaturation at 96uC/
45 sec, 57uC/15 sec, and 69uC/45 sec. The amplified PCR
products were separated and visualized on 2% agarose gel. For
quantification, densitometric analysis was done using image J
software (NIH); GAPDH was used for normalization. The percent
of integrated HIV-1 DNA was calculated relative to positive
control (24 h after infection with VSV-HIV-1) as given below:
% integrated HIV   1 DNA~ DUTreatment=DUGAPDH ðÞ ½ =
DUControl=DUGAPDH ðÞ     100, where DU~ densitometricunits:
Cytotoxicity assay
TZM-bl or HeLa cells were seeded in 96-well plates at a density
of 2.5610
4. Jurkat cells were seeded at a density of 5.0610
4 per
well. We cultured the cells overnight and, next day, treated the
cells with luteolin or control in triplicate. After 24 or 48 h, we
measured the viability of cells after removing the culture medium
and adding 100 ml PBS containing 10 ml of cell counting kit-8
(CCK-8) reagent (Dojindo Molecular Technologies, MD). After
3 h of incubation at 37uC, we collected the supernatants and
measured the absorbance at 450 nm wavelength on a multi-mode
microplate reader (BioTek instruments, VT) [42]. The percent of
viability was calculated as (ODtest/ODcell control)6100. For human
PBMCs, MTT assay was done by adding 20 ml of MTT reagent
(Sigma) from 5 mg/ml stock prepared in PBS. The cells were
incubated with MTT reagent for 3 h, after which 100 mlo f
isopropanol was added to dissolve formazan crystals. Absorbance
was monitored at 570 nm wavelength on a microplate reader
(BioTek instruments).
Statistics
The results were represented as mean 6 SEM for each bar
graph plotted using Sigma plot v8.0 with associated p values for
each treatment group compared to its controls. Statistical analysis
was done using Origin 6.1 software. The significance between two
groups was calculated using a two-tailed student’s t-test followed
by one-way analysis of variance. P,0.05 was considered to be
significant.
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